$BEAT: HeartBeam Traded Its Share Count Seven Times Over on an FDA Badge That Clears Nothing. Pricing the Breakthrough
HeartBeam spiked as much as 119% on an FDA Breakthrough Device Designation for at-home heart attack detection. The indication is not cleared, a $25M ATM equals two-thirds of the market cap, and Nasdaq's clock runs out December 28. We priced all four paths.
On Monday, HeartBeam (Nasdaq: BEAT) traded 402 million shares. The company has 56.3 million shares outstanding. The entire share count turned over roughly seven times in a single session, the stock touched $0.95 intraday, up as much as 119% from Friday's $0.4346 close, and finished at $0.6542, a 50% daily gain. The trigger was a single press release: the FDA granted HeartBeam Breakthrough Device Designation for its system as a tool for assessing potential heart attacks at home.
Here is the part the stream mostly skipped: a Breakthrough Device Designation clears nothing. HeartBeam's heart attack indication is not FDA cleared, is not for sale in the United States or anywhere else, and the pivotal study that would support clearance has not yet been designed in final form. The company itself says it expects to seek FDA alignment on the pivotal study design "in the coming months," with enrollment to follow. What the market repriced on Monday was not a product. It was a regulatory badge, a genuinely useful one, attached to a microcap with a $25 million at-the-market facility, a December 28 Nasdaq compliance deadline, and a share count that has more than doubled in under two years.
What HeartBeam Actually Makes
HeartBeam's core asset is a credit-card-sized ECG device built on what it calls 3D ECG technology: it captures the heart's electrical signal in three non-coplanar directions and then uses a personalized transformation matrix to synthesize a full 12-lead ECG, the clinical standard, from a device a patient can carry in a wallet. The synthesis approach has real clinical validation behind it. In the VALID-ECG pivotal study, 198 patients across five U.S. sites including Mount Sinai and Northwell Health, the synthesized 12-lead showed 93.4% overall diagnostic agreement with a simultaneously recorded standard 12-lead ECG. That dataset supported an FDA clearance in December 2025, but for arrhythmia assessment only.
The heart attack use case is the much bigger prize, and it is the one Monday's designation covers. The clinical logic is straightforward: when chest pain starts, the time to a diagnostic-quality ECG largely determines outcomes, and almost nobody has a 12-lead at home. HeartBeam pegs the myocardial infarction opportunity at roughly $15 billion inside a cardiac platform opportunity it puts above $40 billion. Those are company estimates and should be read as such, but the unmet need is not in dispute.
There is also a newer wrinkle that matters for how you model this company. In June 2026, HeartBeam reorganized around a licensing model: rather than selling devices directly, it intends to license the 3D ECG platform to partners across five channels, from ECG equipment makers and patch vendors to consumer wearables. The former CEO moved to a consulting role, founder Branislav Vajdic and Executive Chairman Rich Ferrari took the wheel, and costs came down. A licensing company with a Breakthrough badge and a cleared synthesis engine is a different asset than a device startup burning cash on a sales force. Whether anyone signs is the open question.
So the setup going into the rest of this week: a 50% repricing on a designation that accelerates but does not approve, a genuine dated catalyst at the end of the month when the ALIGN-ACS heart attack data gets presented at TCT 2026, and underneath it all a Nasdaq clock that runs out December 28 and a dilution machine that just got switched on at exactly the prices the stock is trading at now. What is the badge actually worth, what does the cash clock look like, and where are the zones if the TCT data lands or the ATM grinds the rally down? That is what the rest of this briefing prices out.
Get the next briefing free in your inbox before the stream reads the filings: Join AlphaBriefing
The rest of this briefing is for paid members: the SEC-verified share count and dilution history, the real mechanics of what a Breakthrough Designation buys with Medicare, the cash runway math against a $25 million ATM that equals two-thirds of the market cap, the December 28 Nasdaq math nobody on the stream is doing, and scenario-by-scenario price zones for all four paths from here.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish, the analysis private intel clients pay four figures for, at a fraction of that.